CellPly: Funding, Investors & Team (Sep 2026)
Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization of cancer immunotherapies, cell therapies and cell-based biotherapeutics. The company aims to support the development of novel cancer immunotherapies by accelerating R&D, automating the quality control and advancing the ability to monitor the clinical response to these treatments. Through the use of proprietary microfluidic technologies with Co-Culture Array technology, highly-automated analytical instruments and AI-powered image and data analytics, Cellply products define the function of the immune system one cell at a time, combining functional data with other multiplex data and providing unprecedented single-cell analytical solutions.
CellPly has raised $2.3M across 1 funding round on record, the most recent an undisclosed round of $2.3M announced in Dec 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CellPly Company Profile and Key Stats
Latest funding round on record: Dec 2021.
CellPly Funding Rounds
CellPly Founders and Leadership Team
No contact details are on record for this team yet.
CellPly Funding Compared to Other Biotechnology Startups
CellPly's latest round of $2.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CellPly in Biotechnology and Bologna
Companies Similar to CellPly
NOUS is a biotech startup working on developing a new era of ingredients for Food&Beverage and Nutraceutical…
Yeastime's value proposition is its innovative retrofitting ultrasound technology, which accelerates…
Oraigo is a leading company in the development of innovative road safety technology, utilizing brain-computer…
FTnet is a digital platform in the pharmaceutical industry that employs advanced technology to connect…
Genoa Instruments is a cutting-edge startup focused on revolutionizing biomedical and health research using…
Resalis Therapeutics is focusing on addressing metabolic diseases by targeting a key regulator linked to…
CoRe is an Italian start-up, aimed at the study of new product and process solutions in the field of…
Established in 1999, PHSE is a leading provider of time-sensitive and temperature-controlled transport…
MOGU, an Italian-based European company, is dedicated to developing a variety of mycelium-based technologies…
A biotech business called DIAMANTE (Nano-Technologies for Autoimmune Disease) is dedicated to using plants to…
Relicta developed a water-soluble, transparent and biodegradable plastic for packaging made from fish…
CellPly Funding FAQs
What does CellPly do?
Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization of cancer immunotherapies, cell therapies and cell-based biotherapeutics. The company aims to support the development of novel cancer immunotherapies by accelerating R&D, automating the quality control and advancing the ability to monitor the clinical response to these treatments. Through the use of proprietary microfluidic technologies with Co-Culture Array technology, highly-automated analytical instruments and AI-powered image and data analytics, Cellply products define the function of the immune system one cell at a time, combining functional data with other multiplex data and providing unprecedented single-cell analytical solutions.
How much funding has CellPly raised?
CellPly has raised $2.3M across 1 round on record. The most recent is an undisclosed round of $2.3M announced in Dec 2021.
When did CellPly last raise funding?
CellPly's most recent funding round on record is an undisclosed round of $2.3M, announced in Dec 2021.
Who is the CEO of CellPly?
Massimo Bocchi is listed as CEO at CellPly.
Where is CellPly headquartered?
CellPly is based in Bologna, Emilia-Romagna, Italy.
How many employees does CellPly have?
CellPly is in the 11-50 employee band.
How does CellPly's funding compare to other Biotechnology startups?
CellPly's latest round of $2.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's CellPly Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CellPly is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.